1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYX
ARYx Therapeutics, Inc.US flagOther OTC
0.00
USD
- -
- -
16,731.00Market Cap
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
TTM
Revenue per Share
- -
- -
- -
4.66
1.24
1.04
- -
- -
Basic EPS, GAAP
-16.67
-24.27
-30.73
-26.84
-8.24
-1.65
-1.21
-0.57
Free Cash Flow per Basic Share
- -
- -
-28.88
-5.08
-8.43
-2.42
-1.28
-0.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-74.54
-93.48
-36.67
-8.12
-6.82
-6.22
Tangible Book Value per Share
-53.49
- -
-73.72
-92.06
10.56
1.45
-0.11
-0.24
Basic Weighted Avg Shares
1
1
1
1
3
19
27
32
Sales/Revenue/Turnover
- -
- -
- -
5
4
20
- -
- -
Operating Margin (%)
- -
- -
- -
-596.92
-692.64
-154.21
- -
- -
Depreciation Expense
- -
- -
1
1
1
1
1
1
Net Income, GAAP
-14
-21
-28
-27
-28
-31
-33
-18
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-576.66
-662.84
-158.27
- -
- -
Working Capital
- -
- -
20
40
51
35
- -
-4
LT Debt
- -
- -
9
7
3
13
7
5
Total Equity
-19
- -
-67
-94
35
27
-3
-8
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
ST Debt
4
3
7
LT Borrowings
4
4
5
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
24
13
13

Working Capital

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
Total Current Assets
7
2
4
Cash, Cash Equivalents & STI
6
1
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
6
8
Payables & Accruals
3
3
1
ST Debt
4
3
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.87%
-110.64%
Free Cash Flow
- -
- -
-23.45%
Net Income, GAAP
- -
10.47%
6.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
1
1
18
- -
20
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.54
-0.67
0.18
- -
-1.65
2009
-0.36
-0.34
-0.3
- -
-1.21
2010
-0.22
-0.11
-0.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Paul Goddard
Full Time Employees
56
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
6300 Dumbarton Circle Fremont CA United States of America 94555
IPO Date
Nov 7, 2007
Website
aryx.com
Similar Companies
Allied Corp. (ALID)
Evotec SE (EVT.SW)
Delta 9 Cannabis Inc. (DLTNF)
CanaQuest Medical Corp. (CANQF)
Delivra Health Brands Inc. (DHB.V)
Boiron S.A. (BOIRF)
Business
ARYx Therapeutics, Inc. (ARYX) is a biopharmaceutical company that discovers and develops novel therapies for large, chronic disease markets using its proprietary RetroMetabolic Drug Design technology to create structurally unique molecules that mimic the efficacy of established drugs while avoiding specific safety liabilities through safer metabolic pathways. The company focuses on orally administered treatments for conditions including gastrointestinal disorders, atrial fibrillation, thrombosis risk, and psychiatric disorders; its historical clinical-stage product candidates have included ATI-7505 (a prokinetic agent for chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease), budiodarone (previously ATI-2042, an oral anti-arrhythmic for atrial fibrillation), tecarfarin (previously ATI-5923, an oral anticoagulant for patients at risk of dangerous blood clots), and ATI-9242 (a next-generation atypical antipsychotic for schizophrenia and other psychiatric conditions). Founded in 1997 and headquartered in Fremont, California, ARYx Therapeutics operates primarily in the United States with a pipeline targeting patients requiring chronic oral therapies. In recent years, the company has maintained a development focus on its core pipeline amid limited public updates, with historical advancements including a $35 million committed equity financing facility secured in 2009 to support partnering activities for its advanced compounds and a $30.4 million Series E financing completed in 2006 to advance three clinical programs through Phase 2 proof-of-concept. ARYx Therapeutics went public via IPO in November 2007 and trades on OTC markets under the ARYX ticker, employing approximately 56 full-time staff as of recent profiles. No major acquisitions, new product launches, or strategic alliances have been publicly reported in the last 1-2 years, reflecting a low-profile operational status typical for development-stage biopharma firms reliant on partnerships for commercialization.